No Data
No Data
Positive Week for Neumora Therapeutics, Inc. (NASDAQ:NMRA) Institutional Investors Who Control 42% of the Company
Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders
Analysts Offer Insights on Healthcare Companies: Relmada Therapeutics (RLMD) and Neumora Therapeutics, Inc. (NMRA)
Neumora Therapeutics Price Target Maintained With a $23.00/Share by Needham
Express News | 5Needham Reiterates Buy on Neumora Therapeutics, Maintains $23 Price Target
Neumora Therapeutics' Advancing Drug Pipeline Supports Buy Rating
No Data